Michael Roach, DO
Family Medicine · Ashland, MONPI 1740592435
Payments from drug & device makers
Across 360 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$743
- Novo Nordisk$742
- Lilly USA, LLC$567
- Otsuka America Pharmaceutical, Inc.$558
- Pfizer$424
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,062100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,020 |
| AstraZeneca | 35 | $743 |
| Novo Nordisk | 51 | $742 |
| Lilly USA, LLC | 33 | $567 |
| Otsuka America Pharmaceutical, Inc. | 29 | $558 |
| Pfizer | 29 | $424 |
| Amgen | 17 | $284 |
| Axsome Therapeutics, Inc. | 9 | $187 |
| Lundbeck LLC | 9 | $161 |
| Boehringer Ingelheim | 8 | $138 |
| Exact Sciences | 7 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $116 |
| Astellas Pharma US Inc | 6 | $113 |
| GSK | 7 | $99 |
| Abbott | 5 | $98 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Dexcom, Inc. | 2 | $57 |
| Johnson & Johnson | 4 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Merck | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Bayer | 2 | $44 |
| Novartis | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Antares Pharma, Inc. | 2 | $27 |
| Biogen | 1 | $24 |
| UCB, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,062 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $95,180 |
| MounjaroTirzepatide | 62 | $89,588 |
| JardianceEmpagliflozin | 99 | $88,995 |
| EliquisApixaban | 50 | $48,793 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $40,975 |
| TrulicityDulaglutide | 36 | $38,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,506 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $22,108 |
| FarxigaDapagliflozin Propanediol | 21 | $21,239 |
| XareltoRivaroxaban | 19 | $19,284 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $17,097 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,753 |
| JanuviaSitagliptin Phosphate | 13 | $11,608 |
| MyrbetriqMirabegron | 16 | $11,292 |
| LinzessLinaclotide | 13 | $9,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $567 | $127,90098 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $742 | $112,278102 claims |
| Boehringer IngelheimJardiance | $138 | $88,99599 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $743 | $62,21585 claims |
| PfizerEliquis | $424 | $48,79350 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $99 | $30,50248 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $45 | $22,10827 claims |
| Johnson & JohnsonXarelto | $54 | $19,28419 claims |
| MerckJanuvia | $45 | $11,60813 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $11,29216 claims |
| AbbVieLinzess | $1,020 | $9,24813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Ashland
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.